Greenridge Global Issues Pessimistic Forecast for EUDA Health (NASDAQ:EUDA) Stock Price

EUDA Health (NASDAQ:EUDA) had its price objective decreased by investment analysts at Greenridge Global from $6.00 to $2.75 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Greenridge Global’s price objective would indicate a potential upside of 438.48% from the company’s current price. Greenridge Global also issued estimates for EUDA Health’s FY2025 earnings at ($0.01) EPS.

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of EUDA Health in a research report on Friday, January 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.75.

EUDA Health Stock Performance

Shares of EUDA opened at $0.51 on Monday. The company has a 50 day moving average price of $1.37 and a 200-day moving average price of $2.01. The stock has a market capitalization of $19.31 million, a PE ratio of -4.26 and a beta of -0.11. EUDA Health has a fifty-two week low of $0.46 and a fifty-two week high of $4.30.

Hedge Funds Weigh In On EUDA Health

A hedge fund recently raised its stake in EUDA Health stock. Citadel Advisors LLC raised its holdings in shares of EUDA Health Holdings Limited (NASDAQ:EUDA) by 57.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,631 shares of the company’s stock after purchasing an additional 16,321 shares during the period. Citadel Advisors LLC owned 0.12% of EUDA Health worth $78,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.35% of the company’s stock.

About EUDA Health

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.